Press coverage about Exactech (NASDAQ:EXAC) has been trending somewhat positive on Wednesday, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Exactech earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 46.6360972130564 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Hip Reconstruction Devices Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2022 (bizjournals.com)
- Hip Articular Prostheses Market Growth Study 2017 to 2022 CHUNLI, Stryker, EXACTECH INC, Biomet UK LTD (openpr.com)
- Polymer Orthopaedic Biomaterial Market 2017 -Acumed, Exactech Inc, Stryker Corporation (sbwire.com)
- Knee Implants Market – Global Industry Insights, Trends, and Opportunity Analysis, 2025 (mynewsdesk.com)
- Global Hip Replacement Implants Market is Determined to Cross US$ 9 Billion By 2024 (medgadget.com)
Shares of Exactech (NASDAQ:EXAC) traded down 1.07% during midday trading on Wednesday, hitting $32.25. The stock had a trading volume of 23,380 shares. The company has a market cap of $461.05 million, a P/E ratio of 3225.00 and a beta of 1.01. Exactech has a one year low of $22.20 and a one year high of $34.25. The firm has a 50 day moving average of $31.66 and a 200-day moving average of $29.92.
Exactech (NASDAQ:EXAC) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.33. Exactech had a net margin of 0.30% and a return on equity of 7.39%. The business had revenue of $67.30 million for the quarter, compared to analyst estimates of $67.75 million. During the same quarter last year, the business earned $0.31 earnings per share. The business’s revenue for the quarter was up 1.8% on a year-over-year basis. On average, analysts forecast that Exactech will post $1.29 earnings per share for the current fiscal year.
Several brokerages have recently commented on EXAC. Robert W. Baird set a $34.00 price target on Exactech and gave the stock a “buy” rating in a research note on Sunday. BidaskClub raised Exactech from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Finally, Gabelli reissued a “buy” rating on shares of Exactech in a research note on Monday, July 31st.
ILLEGAL ACTIVITY NOTICE: “Exactech (EXAC) Earns Coverage Optimism Score of 0.09” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2968916/exactech-exac-earns-coverage-optimism-score-of-0-09.html.
In related news, Director Fern Watts sold 1,013 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total transaction of $29,417.52. Following the transaction, the director now owns 4,727 shares in the company, valued at $137,272.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 28.30% of the stock is owned by company insiders.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.